{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T12:56:27Z","timestamp":1648990587255},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,3,6]],"date-time":"2013-03-06T00:00:00Z","timestamp":1362528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s00108-012-3202-7","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T02:44:33Z","timestamp":1362451473000},"page":"449-463","source":"Crossref","is-referenced-by-count":1,"title":["Antizytokintherapie"],"prefix":"10.1007","volume":"54","author":[{"given":"L.","family":"Naumann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Feist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.-R.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,6]]},"reference":[{"key":"3202_CR1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/316552a0","volume":"316","author":"Beutler","year":"1985","unstructured":"Beutler B, Greenwald D, Hulmes JD et\u00a0al (1985) Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316:552\u2013554","journal-title":"Nature"},{"key":"3202_CR2","doi-asserted-by":"crossref","unstructured":"Dinarello CA, Cannon JG, Wolff SM et\u00a0al (1986) Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin\u00a01. J\u00a0Exp Med 163:1433\u20131450","DOI":"10.1084\/jem.163.6.1433"},{"key":"3202_CR3","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","volume":"344","author":"Elliott","year":"1994","unstructured":"Elliott MJ, Maini RN, Feldmann M et\u00a0al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105\u20131110","journal-title":"Lancet"},{"key":"3202_CR4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","volume":"36","author":"Furst","year":"2006","unstructured":"Furst DE, Wallis R, Broder M et\u00a0al (2006) Tumor necrosis factor antagonists: different kinetics and\/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36:159\u2013167","journal-title":"Semin Arthritis Rheum"},{"key":"3202_CR5","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P et\u00a0al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60:1884\u20131894","journal-title":"Arthritis Rheum"},{"key":"3202_CR6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0169-409X(02)00026-1","volume":"54","author":"Chapman","year":"2002","unstructured":"Chapman AP (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54:531\u2013545","journal-title":"Adv Drug Deliv Rev"},{"key":"3202_CR7","doi-asserted-by":"crossref","unstructured":"Lipsky PE, Heijde DM van der, St Clair EW et\u00a0al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N\u00a0Engl J Med 343:1594\u20131602","DOI":"10.1056\/NEJM200011303432202"},{"key":"3202_CR8","doi-asserted-by":"crossref","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD et\u00a0al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N\u00a0Engl J Med 340:253\u2013259","DOI":"10.1056\/NEJM199901283400401"},{"key":"3202_CR9","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT et\u00a0al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400\u20131411","journal-title":"Arthritis Rheum"},{"key":"3202_CR10","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","volume":"58","author":"Kay","year":"2008","unstructured":"Kay J, Matteson EL, Dasgupta B et\u00a0al (2008) Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 58:964\u2013975","journal-title":"Arthritis Rheum"},{"key":"3202_CR11","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","volume":"50","author":"St","year":"2004","unstructured":"St\u00a0Clair EW, Heijde DM van der, Smolen JS et\u00a0al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432\u20133443","journal-title":"Arthritis Rheum"},{"key":"3202_CR12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","volume":"372","author":"Emery","year":"2008","unstructured":"Emery P, Breedveld FC, Hall S et\u00a0al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372:375\u2013382","journal-title":"Lancet"},{"key":"3202_CR13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF et\u00a0al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26\u201337","journal-title":"Arthritis Rheum"},{"key":"3202_CR14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK et\u00a0al (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase\u00a0III trial. Lancet 374:210\u2013221","journal-title":"Lancet"},{"key":"3202_CR15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/ar3147","volume":"12","author":"Krieckaert","year":"2010","unstructured":"Krieckaert CL, Bartelds GM, Lems WF et\u00a0al (2010) The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 12:217","journal-title":"Arthritis Res Ther"},{"key":"3202_CR16","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Alvarez R, D\u00edaz-Lagares C, Garc\u00eda-Hern\u00e1ndez F et\u00a0al (2011) Hepatitis\u00a0B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257\u00a0cases. Medicine (Baltimore) 90:359\u2013371","DOI":"10.1097\/MD.0b013e3182380a76"},{"key":"3202_CR17","doi-asserted-by":"crossref","unstructured":"Mackey AC, Green L, Liang LC et\u00a0al (2007) Hepatosplenic T\u00a0cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J\u00a0Pediatr Gastroenterol Nutr 44:265\u2013267","DOI":"10.1097\/MPG.0b013e31802f6424"},{"key":"3202_CR18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","volume":"58","author":"Listing","year":"2008","unstructured":"Listing J, Strangfeld A, Kekow J et\u00a0al (2008) Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 58:667\u2013677","journal-title":"Arthritis Rheum"},{"key":"3202_CR19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbspin.2008.04.016","volume":"76","author":"Berthelot","year":"2009","unstructured":"Berthelot JM, De Bandt M, Goupille P et\u00a0al (2009) Exposition to anti-TNF drugs during pregnancy: outcome of 15\u00a0cases and review of the literature. Joint Bone Spine 76:28\u201334","journal-title":"Joint Bone Spine"},{"key":"3202_CR20","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","volume":"87","author":"Dinarello","year":"1996","unstructured":"Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87:2095\u20132147","journal-title":"Blood"},{"key":"3202_CR21","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/ard.2004.032060","volume":"64","author":"Alexander","year":"2005","unstructured":"Alexander T, Klotz O, Feist E et\u00a0al (2005) Successful treatment of acute visual loss in Muckle-Wells syndrome with interleukin\u00a01 receptor antagonist. Ann Rheum Dis 64:1245\u20131246","journal-title":"Ann Rheum Dis"},{"key":"3202_CR22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/ard.2009.108068","volume":"69","author":"Naumann","year":"2010","unstructured":"Naumann L, Feist E, Natusch A et\u00a0al (2010) IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still\u2019s disease. Ann Rheum Dis 69:466\u2013467","journal-title":"Ann Rheum Dis"},{"key":"3202_CR23","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1073\/pnas.84.20.7251","volume":"S","author":"Gauldie","year":"1987","unstructured":"Gauldie J, Richards C, Harnish D et\u00a0al (1987) Interferon beta\u00a02\/B-cell stimulatory factor type\u00a02 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U\u00a0S\u00a0A 84:7251\u20137255","journal-title":"Proc Natl Acad Sci U"},{"key":"3202_CR24","unstructured":"Kavanaugh A (2012) Abstract\u00a0772, ACR-Kongress"},{"key":"3202_CR25","doi-asserted-by":"crossref","unstructured":"Burmester GR, Weinblatt ME, McInnes IB et\u00a0al (2012) Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis (im Druck). DOI 10.1136\/annrheumdis-2012-202450","DOI":"10.1136\/annrheumdis-2012-202450"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-012-3202-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-012-3202-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-012-3202-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T05:01:50Z","timestamp":1595480510000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-012-3202-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,6]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["3202"],"URL":"https:\/\/doi.org\/10.1007\/s00108-012-3202-7","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,6]]}}}